» Articles » PMID: 19254552

Free-energy Perturbation Simulation on Transition States and Redesign of Butyrylcholinesterase

Overview
Journal Biophys J
Publisher Cell Press
Specialty Biophysics
Date 2009 Mar 4
PMID 19254552
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

It is recognized that an ideal anti-cocaine treatment is to accelerate cocaine metabolism by producing biologically inactive metabolites via a route similar to the primary cocaine-metabolizing pathway, i.e., butyrylcholinesterase (BChE)-catalyzed hydrolysis of cocaine. BChE mutants with a higher catalytic activity against (-)-cocaine are highly desired for use as an exogenous enzyme in humans. To develop a rational design for high-activity mutants, we carried out free-energy perturbation (FEP) simulations on various mutations of the transition-state structures in addition to the corresponding free-enzyme structures by using an extended FEP procedure. The FEP simulations on the mutations of both the free-enzyme and transition-state structures allowed us to calculate the mutation-caused shift of the free-energy change from the free enzyme (BChE) to the transition state, and thus to theoretically predict the mutation-caused shift of the catalytic efficiency (k(cat)/K(M)). The computational predictions are supported by the kinetic data obtained from the wet experiments, demonstrating that the FEP-based computational design approach is promising for rational design of high-activity mutants of an enzyme. One of the BChE mutants designed and discovered in this study has an approximately 1800-fold improved catalytic efficiency against (-)-cocaine compared to wild-type BChE. The high-activity mutant may be therapeutically valuable.

Citing Articles

Long-lasting blocking of interoceptive effects of cocaine by a highly efficient cocaine hydrolase in rats.

Wei H, LeSaint J, Jin Z, Zhan C, Zheng F Sci Rep. 2024; 14(1):927.

PMID: 38195724 PMC: 10776848. DOI: 10.1038/s41598-023-50678-0.


A Key Role in Catalysis and Enzyme Thermostability of a Conserved Helix H5 Motif of Human Glutathione Transferase A1-1.

Chronopoulou E, Mutabdzija L, Poudel N, Papageorgiou A, Labrou N Int J Mol Sci. 2023; 24(4).

PMID: 36835112 PMC: 9959719. DOI: 10.3390/ijms24043700.


Catalytic activities of a highly efficient cocaine hydrolase for hydrolysis of biologically active cocaine metabolites norcocaine and benzoylecgonine.

Shang L, Jin Z, Wei H, Park S, Zhan C, Zheng F Sci Rep. 2023; 13(1):640.

PMID: 36635293 PMC: 9837138. DOI: 10.1038/s41598-022-27280-x.


Protein-Protein Interactions: Insight from Molecular Dynamics Simulations and Nanoparticle Tracking Analysis.

Chong W, Chupradit K, Chin S, Khoo M, Khor S, Tayapiwatana C Molecules. 2021; 26(18).

PMID: 34577167 PMC: 8472368. DOI: 10.3390/molecules26185696.


A Comprehensive Review of Cholinesterase Modeling and Simulation.

De Boer D, Nguyen N, Mao J, Moore J, Sorin E Biomolecules. 2021; 11(4).

PMID: 33920972 PMC: 8071298. DOI: 10.3390/biom11040580.


References
1.
Pan Y, Gao D, Yang W, Cho H, Yang G, Tai H . Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci U S A. 2005; 102(46):16656-61. PMC: 1283827. DOI: 10.1073/pnas.0507332102. View

2.
Masson P, Xie W, Froment M, Levitsky V, Fortier P, Albaret C . Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates. Biochim Biophys Acta. 1999; 1433(1-2):281-93. DOI: 10.1016/s0167-4838(99)00115-6. View

3.
Gao D, Zhan C . Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase. Proteins. 2005; 62(1):99-110. PMC: 2882100. DOI: 10.1002/prot.20713. View

4.
Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps J, Nachon F . Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem. 2003; 278(42):41141-7. DOI: 10.1074/jbc.M210241200. View

5.
Gorelick D . Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend. 1998; 48(3):159-65. DOI: 10.1016/s0376-8716(97)00119-1. View